Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Oncotype DX® on Treatment Recommendation of for Early-stage Hormone Receptor-positive Breast Cancer and Its Economic Evaluation Under the Brazilian Society Perspective

NCT05100277 is registered in ClinicalTrials.gov with Hospital Perola Byington as lead sponsor.

NCT NCT05100277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05100277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Oncotype DX® on Treatment Recommendation of for Early-stage Hormone Receptor-positive Breast Cancer and Its Economic Evaluation Under the Brazilian Society Perspective
Lead sponsor
Hospital Perola Byington
Phase
Observational
Overall status
Completed
Start date
August 8, 2018
Completion date
February 4, 2019
Enrollment
155 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant treatment, breast cancer